Document is current
Any future updates will be listed below
-
Authors
Nicholls, Stephen J.
Ray, Kausik K.
Lincoff, A. Michael
Sarnes, Evelyn
Gillard, Kristin K.
Bloedon, LeAnne
Migliaccio-Walle, Kristen
Elsea, David
Nissen, Steven E.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02993406 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis
https://doi.org/10.1136/bmjopen-2021-048893
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance
https://doi.org/10.1161/circulationaha.123.066213
Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial
https://doi.org/10.1007/s40256-025-00753-w
Bempedoic Acid: A Novel LDL Cholesterol–Lowering Agent
https://doi.org/10.2337/cd20-0038
Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia
https://doi.org/10.2337/cd21-0019
-
Funding
Funding for this research was provided by:
Esperion Therapeutics
Monash University
- License Information
-
More Information
Article History
Accepted: 14 July 2025
First Online: 20 August 2025
Declarations
:
: Dr. Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron; and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, Novo Nordisk, CSL Sequiris, and Vaxxinity. Dr. Ray has received grants to his institution from Amgen, Daiichi Sankyo, Regeneron, and Sanofi; and received consulting fees from Daiichi, Esperion, Amgen, Novartis, Sanofi, Eli Lilly, Silence Therapeutics, Kowa, Bayer, Abbott, AstraZeneca, Cargene, New Amsterdam, Scribe, Vaxxinity, CRISPR, Beren, Novo Nordisk, and Boehringer Ingelheim. Dr. Lincoff has received Esperion research funding; receiving grants from Eli Lilly, AbbVie, CSL, AstraZeneca, and Novartis; and received personal fees from Novo Nordisk, Glaxo, Akebia, Endologix, Fibrogen, Provention, and Becton Dickson. Dr. Nissen has received grants to perform clinical trials from AbbVie, AstraZeneca, Amgen, Bristol Myers Squibb, Eli Lilly, Esperion Therapeutics Inc, Medtronic, MyoKardia, New Amsterdam Pharmaceuticals, Novartis, and Silence Therapeutics.
: Open Access funding enabled and organized by CAUL and its Member Institutions. This study was funded by Esperion Therapeutics, Inc.
: Dr. Sarnes and Ms. Bloedon are employees of Esperion Therapeutics; Dr. Gillard was an employee at the time of this research. Ms. Migliaccio-Walle is an employee of Curta, Inc. and Dr. Elsea was an employee of Curta, Inc. at the time of this research, which received funding to conduct this study. Dr. Nicholls and Dr. Lincoff are Editorial Board members of the American Journal of Cardiovascular Drugs . Dr. Nicholls and Dr. Lincoff were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All authors conceptualized and designed the study. E.S., L.B., and K.K.G. were responsible for project funding and administration. K.M.W. and D.E. conducted the analyses, and S.J.N., K.K.R., E.S., A.M.L., and S.E.N. drafted the manuscript. All authors critically reviewed the manuscript for intellectual content and approved the final version of the manuscript.
: The data will not be shared.
: Not applicable.
: Not applicable.
: Not applicable.
